The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Webcasts|July 30, 2020
Engineering Approaches to Respiratory Drug Delivery: Mannitol Case Study
Author(s)Lonza Pharma & Biotech
If you have a new compound for respiratory drug delivery, what particle engineering approach should you take? This webinar will explore both micronization and spray drying approaches in relation to product performance of the inhaled drug product. Live: Thursday, Jul. 30, 2020 at 11am EDT | 8am PDT | 4pm GMT | 5pm CEST On demand available after airing until Jul. 30, 2021 Register free
Register free:
Event Overview:
Both spray drying and jet milling are commercially viable engineering processes for the development of respirable drug products. This case study explores the material and performance properties of spray-dried and jet-milled mannitol for respiratory delivery. The head-to-head comparison reveals opportunities and risks for designing a product based on each approach.
Key Learning Objectives:
- Understand the pros and cons of spray drying vs. jet milling
- Learn how to conduct a risk assessment to inform engineering technology selection
- Explore how particle morphology influences aerodynamic performance
Speakers: Cameron Kadleck, Respiratory Scientist, Product Development, Lonza
Jimmy Beaty, Respiratory Scientist, Product Development, Lonza
Time and date: Thursday, Jul. 30, 2020 at 11am EDT | 8am PDT | 4pm GMT | 5pm CEST
On demand available after airing until Jul. 30, 2021.
Sponsor: Lonza Pharma & Biotech
Register free:
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.